- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05704283
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
3D Ultrasound Imaging of the Axillary Lymph Nodes
Study Overview
Detailed Description
PRIMARY OBJECTIVES:
I. Conducting a pilot study to optimize the in vivo performance of the newly developed three-dimensional (3D)-ultrasound (US) technology.
II. Evaluate the performance of the new 3D-US technique in differentiating benign from malignant lymph nodes in patients.
III. Compare the performance of the new 3D-US method with conventional two-dimensional (2D)-US for localizing the clipped lymph nodes.
OUTLINE:
Patients undergo 3D-US on study. Patients who have a lymph node clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Contact Backup
- Name: Rica Pol
- Phone Number: 507-422-5118
- Email: Pol.Hanarica@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Contact:
- Rica Pol
- Phone Number: 507-422-5118
- Email: Pol.Hanarica@mayo.edu
-
Principal Investigator:
- Shigao D. Chen, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with lymph node biopsy or lymph node clip placement as per routine clinical care.
- Age of 18 or older.
Exclusion Criteria:
- Vulnerable subjects such as prisoners and adults lacking capacity to consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Diagnostic (3D-US)
Patients undergo 3D-US on study.
Patients who have a lymph node clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.
|
Undergo 3D-US
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lymph node diagnosis by radiologist (benign or malignant) (Aim 2)
Time Frame: Up to 2 years
|
Will characterize the lymph node as benign or malignant by reviewing images from each imaging technique based on clinical criteria including node size, shape, margin, cortical thickness, stiffness, and vascularity obtained from B-mode, shear wave elastography, and Doppler imaging.
Histopathology results will be used as the ground truth to measure sensitivity and specificity of each ultrasound technology for distinguishing between benign and malignant lymph nodes.
The overall agreement of the new 3dimensional (D)-ultrasound (US) method with the biopsy result will be compared to that for 2D-US using McNemar's test.
For clipped lymph nodes, the performance of 2D and 3D-US will be compared for localizing the clips.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shigao D Chen, PhD, Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-006606
- NCI-2023-00106 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R01EB031040 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Carcinoma
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Canadian Cancer Trials GroupActive, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma | Ductal Breast Carcinoma | Tubular Breast Carcinoma | Medullary Breast CarcinomaUnited States, Canada
-
University of Texas at AustinWashington University School of Medicine; Ohio State UniversityCompletedStage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedStage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedInflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast Carcinoma | Tubular Ductal Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Bilateral Breast Carcinoma | Localized Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Bilateral Breast CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in SituUnited States
Clinical Trials on Ultrasound Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
The Hospital for Sick ChildrenCompleted
-
Mayo ClinicTerminated
-
Sunnybrook Health Sciences CentreRecruitingHead and Neck Cancer | Rectal Cancer | Prostate CancerCanada
-
Ohio State University Comprehensive Cancer CenterWithdrawn
-
Rijnstate HospitalRadboud University Medical CenterActive, not recruitingCarotid Artery StenosisNetherlands
-
Mayo ClinicRecruitingOvarian Neoplasms | Ovarian Carcinoma | Adnexal Lesion | Female Reproductive System Neoplasm | Female Reproductive System Adnexal Neoplasm | Ovarian LesionUnited States
-
Imperial College LondonRecruiting
-
Samuel Fernández CarneroCompletedTrigger Point Pain, MyofascialSpain
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation...CompletedBreast Radiotherapy ToxicityUnited Kingdom